- Home
- AMPH
as 11-21-2024 4:00pm EST
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RANCHO CUCAMONGA |
| Market Cap: | 2.5B | IPO Year: | 2014 |
| Target Price: | $63.00 | AVG Volume (30 days): | 404.9K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.01 | EPS Growth: | 17.38 |
| 52 Week Low/High: | $36.56 - $65.92 | Next Earning Date: | 11-06-2024 |
| Revenue: | $723,549,000 | Revenue Growth: | 20.33% |
| Revenue Growth (this year): | 17.23% | Revenue Growth (next year): | 10.25% |
Stock Insider Trading Activity of Amphastar Pharmaceuticals Inc. (AMPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zhou Rong | AMPH | SENIOR EVP, PRODUCTION CENTER | Nov 12 '24 | Sell | $48.88 | 6,893 | $336,929.84 | 118,388 | |
| PRINS RICHARD K | AMPH | Director | Nov 12 '24 | Sell | $48.80 | 5,000 | $243,985.50 | 31,471 | |
| Zhou Rong | AMPH | SENIOR EVP, PRODUCTION CENTER | Sep 13 '24 | Sell | $48.26 | 3,000 | $144,784.50 | 118,388 | |
| Petersen Floyd F. | AMPH | Director | Sep 5 '24 | Sell | $46.47 | 3,000 | $139,417.20 | 75,409 | |
| Zhou Rong | AMPH | SENIOR EVP, PRODUCTION CENTER | Aug 26 '24 | Sell | $48.35 | 4,000 | $193,400.00 | 118,388 |
Latest Amphastar Pharmaceuticals Inc. News
AMPH Breaking Stock News: Dive into AMPH Ticker-Specific Updates for Smart Investing
ACCESSWIRE
8 days ago
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Argus Research
9 days ago
AMPH: Lowering target price to $50.00
Simply Wall St.
14 days ago
Amphastar Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations
Thomson Reuters StreetEvents
14 days ago
Q3 2024 Amphastar Pharmaceuticals Inc Earnings Call
GuruFocus.com
15 days ago
Amphastar Pharmaceuticals Inc (AMPH) Q3 2024 Earnings Call Highlights: Resilient Revenue Growth ...
Zacks
15 days ago
Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings
Zacks
15 days ago
Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates
Associated Press Finance
15 days ago
Amphastar: Q3 Earnings Snapshot
Compare AMPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMPH Amphastar Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.